Leptin: A Marker for AML Chemo-Sensitivity

In this prospective study, we will collect bone marrow supernatant samples from patients diagnosed with Acute Myeloid Leukemia (AML) to evaluate the levels of leptin. Our aim is to explore whether elevated leptin levels can serve as a predictive biomarker for poor treatment outcomes following standard chemotherapy regimens. The findings may help in stratifying patient risk and personalizing therapeutic approaches in AML treatment.

Inclusion criteria

• Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)";
• All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;
• Patients participate in the study accompanied by family members and sign informed consent documents.

Exclusion criteria

• Patients with concurrent malignancies requiring treatment;
• Presence of infectious diseases, including SARS, viral hepatitis, or HIV/ AIDS;
• Major surgery performed within the last 21 days;
• Performance Status (PS) score >3;
• Severe liver or kidney dysfunction or serious infection;
• Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.